WuXi AppTec has co-led a $98m series D round for China-focused drug developer Canbridge Pharmaceuticals that also featured fellow corporate Tigermed.
China-based biopharmaceutical company Canbridge Pharmaceuticals closed a $98m series D round yesterday co-led by pharmaceutical research and development firm WuXi AppTec and growth equity firm General Atlantic.
Contract research services provider Tigermed also contributed to the round, as did investment manager RA Capital Management, hedge fund Hudson Bay Capital Management and private equity firm YuanMing Prudence Fund.
WuXi AppTec and General Atlantic each have the option to provide up to an additional $10m in funding, should Canbridge meet certain conditions.
…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
